The Norwood Scale Has Lasted 50 Years. Here’s Why Dermatologists Still Use It. matters only if it helps someone read their pattern more clearly and choose the next step with realistic expectations. Classification, timeline, and evidence beat guesswork every time.
Last fall, a 28-year-old software developer named Kevin sent me a message through a contact form. He’d spent three hours that night on Reddit comparing photos of his hairline to Norwood illustrations, cycling between “I’m definitely a 2” and “Oh God, I’m a 3.” He attached four selfies taken in different bathroom lighting, each one telling a slightly different story. He wanted to know which image was “the real one.” I get some version of Kevin’s question every week, and the answer is always the same: a classification system is only as good as the conditions under which you apply it. But the fact that Kevin instinctively reached for the Norwood scale, and not any of its competitors, says something about why this 50-year-old framework still dominates clinical hair loss assessment.
This piece covers what the Norwood scale actually measures, the biology it’s trying to capture, and the practical reality of staging yourself versus getting staged by a clinician. The thesis is simple: the Norwood scale endures not because it’s perfect, but because it’s useful enough to stay ahead of every replacement proposed since 1975.
Hamilton Started It, Norwood Made It Stick
The history begins with James Hamilton’s 1951 paper in the Annals of the New York Academy of Sciences. Hamilton noticed something that now seems obvious but was genuinely revelatory at the time: men castrated before puberty didn’t develop the characteristic temple recession and crown thinning of androgenetic alopecia. No androgens, no pattern baldness. That observation anchored the hormonal model of male hair loss.
Hamilton’s original classification was simple, maybe too simple, with only a few broad stages. O’Tar Norwood’s 1975 paper in the Southern Medical Journal expanded it into the seven-stage system (plus Type A variants) that dermatologists still reference today. The Type A variant is worth knowing about because it describes a front-to-back recession pattern rather than the more common bitemporal-plus-vertex combination. Many men fall somewhere between the classic and Type A presentations, which is one of the system’s acknowledged weaknesses.
Alternative systems have been proposed. The basic and specific (BASP) classification from 2007 tried to offer more granularity. It never gained real traction in clinical practice, not because it was worse on paper, but because the Norwood scale had already become the shared language of dermatology referrals, clinical trials, and transplant planning. It’s like QWERTY. Not optimal, but the switching costs are enormous.
The Biology Underneath the Stages
The Norwood scale is really just a visual proxy for follicular miniaturization, which is itself driven by dihydrotestosterone (DHT). Here is the practical read of the mechanism:
Testosterone gets converted to DHT by the 5-alpha reductase enzyme. In follicles that are genetically susceptible (and location matters enormously; the occipital “safe zone” is largely spared), DHT binds to the androgen receptor in the dermal papilla and gradually shortens the growth phase of each hair cycle. Over successive cycles, terminal hairs become thinner, shorter, lighter. Eventually they’re vellus hairs, essentially invisible. That shrinkage process is miniaturization.
The genetics are polygenic, which is a clinical way of saying “it’s complicated.” The androgen receptor gene sits on the X chromosome, so the maternal grandfather comparison has some basis, but paternal contributions and multiple autosomal loci also matter. Telling a patient “look at your mom’s dad” is a rough heuristic, not a diagnosis.
Two drugs exploit this pathway directly. Finasteride blocks the type II isoform of 5-alpha reductase. Dutasteride blocks both type I and type II, producing more aggressive DHT reduction, with correspondingly greater effects on hair density in head-to-head trials (Olsen et al., JAAD, 2006). That difference matters clinically, but dutasteride is only approved for benign prostatic hypertrophy and is used off-label for hair.
What a Dermatology Workup Actually Looks Like
Kevin’s bathroom selfies were a starting point, not a finish line. A proper evaluation by a dermatologist typically includes:
History. Timeline of loss. Progressive or episodic? Medications, recent illness, dietary changes (crash diets and rapid weight loss reliably trigger telogen effluvium). Family history on both sides.
Scalp exam and trichoscopy. Dermoscopy of the scalp adds resolution the naked eye can’t match. In androgenetic alopecia, the hallmarks are hair shaft diameter variability (caliber variability exceeding 20%), yellow dots at empty follicular ostia, and decreased follicular unit density in the affected zones with the occipital area still intact.
Selective lab work. The AAD doesn’t recommend routine androgen panels in men with a classic pattern. Lab testing makes more sense when you suspect telogen effluvium or diffuse thinning: ferritin, TSH, vitamin D, CBC. Ferritin below 30 ng/mL in women, or below 50 ng/mL when hair loss is a concern, warrants iron repletion.
Standardized photography. Front, top, sides, back, consistent distance and lighting, reproducible head position. Without this, tracking change over months is guesswork.
Patients looking for a detailed reference on how to self-stage before or between clinical visits can review this guide, which provides photographic staging examples and additional clinical context. Self-staging is not a substitute for a clinical evaluation, but it gives you a shared vocabulary when you do see a dermatologist.
Treatment: Ranked by Evidence, Not Hype
I’ll be blunt: the most effective time to start treatment is before you think you need it. Once a follicle is miniaturized beyond a certain point, you’re managing decline rather than reversing it. Here’s what the evidence actually supports:
Oral finasteride 1 mg daily. The largest evidence base of any hair loss medication. The pivotal five-year trial (JAAD, 2002) showed sustained hair count improvements versus placebo. Sexual side effects affect a small percentage in randomized trials and are generally reversible on discontinuation. Generic finasteride costs $10 to $25 per month at US pharmacies with discount cards, sometimes $5 to $15 through telehealth. Branded Propecia at $70 to $90 monthly buys you identical molecules in fancier packaging.
Topical minoxidil 5%, twice daily. FDA-approved for OTC use. The mechanism isn’t fully understood but involves potassium channel opening and a direct follicular effect that prolongs anagen. Visible response typically shows at three to six months. Generic runs $10 to $30 monthly; branded Rogaine about double. Foam and solution are clinically equivalent, though foam causes less scalp irritation in some patients.
Low-dose oral minoxidil (0.25 to 5 mg daily). This got a significant credibility boost after Vañó-Galván et al. published safety data on 1,404 patients in JAAD in 2021. The side-effect profile at low doses is more manageable than the old cardiovascular formulation’s reputation would suggest, though periorbital edema and hypertrichosis do occur. Generic, under $15 per month.
Platelet-rich plasma and microneedling. JAMA Dermatology has published several smaller randomized trials with positive but variable findings. These are adjuncts, not monotherapy. PRP runs $500 to $1,500 per session, with most protocols calling for three to four sessions in year one. Over a full year, that can cost more than combination medical therapy.
Hair transplantation (FUE/FUT). The only intervention that physically moves follicles from donor to recipient areas. FUE in the US runs $4 to $10 per graft, which for a typical 2,500 to 3,500 graft case puts you at $10,000 to $35,000. In Turkey, $2,000 to $5,000 for similar graft counts. The price difference reflects labor costs and clinic overhead, not a straightforward quality gap, but due diligence matters enormously when you’re shopping on price alone.
Insurance generally classifies all of this as cosmetic. HSAs and FSAs may cover prescribed medications and physician visits but typically not surgery.
The Lifestyle Factors That Actually Matter (and the Ones That Don’t)
Pattern hair loss is genetically determined. Full stop. But several factors influence the rate of progression:
Smoking accelerates loss through microvascular damage, oxidative stress, and effects on circulating androgens. Cross-sectional studies show higher AGA rates in smokers versus matched nonsmokers. If you needed another reason to quit, here it is.
Severe stress can trigger telogen effluvium two to three months after the precipitating event. It typically resolves within six to nine months, but it can unmask underlying pattern loss that was quietly progressing.
Anabolic steroid use supercharges androgenetic alopecia in susceptible men. The effects may not fully reverse after discontinuation.
Biotin supplements, on the other hand, do essentially nothing for hair in patients without documented biotin deficiency. Worse, biotin interferes with several common lab assays, including thyroid function and troponin. That’s a real problem if you’re also getting bloodwork done.
Diet matters only at the extremes. Severe caloric restriction, very low protein intake, rapid weight loss: these all reliably produce telogen effluvium. But “eating cleaner” or adding collagen powder to your smoothie won’t override your androgen receptor genetics.
See also: How Crypto Mining Works Explained Simply
When Self-Management Isn’t Enough
Several scenarios warrant getting off Reddit and into a dermatologist’s office:
Sudden, diffuse shedding within the past six months points toward telogen effluvium, which requires investigating the trigger, not starting finasteride. Patchy, smooth bald spots suggest alopecia areata, an autoimmune condition with a completely different treatment pathway. Scalp pain, burning, redness, scaling, or visible scarring raises concern for lichen planopilaris, frontal fibrosing alopecia, or central centrifugal cicatricial alopecia, conditions where prompt diagnosis can prevent permanent follicle destruction. Rapid progression (more than one Norwood stage per year in a young patient) deserves in-person confirmation and early intervention planning.
The AAD’s position is that any progressive hair loss concerning to the patient is a legitimate reason for consultation. I’d add: if you’ve been on standard medical therapy for 12 months with documented compliance and aren’t seeing results, get reassessed. Something else might be going on.
FAQs
How fast does pattern hair loss progress? It varies enormously. Some men move one Norwood stage every few years; others plateau and stay stable for a decade. Age of onset, family history, and recent rate of change are the strongest predictors.
Is oral minoxidil better than topical? Low-dose oral minoxidil produces comparable effects to topical with better adherence in many patients. The trade-off is a slightly different side-effect profile. Work with a prescribing clinician to decide.
Can diet alone slow hair loss? Diet can fix contributing factors like iron deficiency or the shedding caused by crash dieting. It cannot stop the androgen-driven miniaturization process.
Is the Norwood scale used for women? No. Female pattern hair loss is classified using the Ludwig or Savin scales, which capture the diffuse central thinning pattern more common in women.
Do biotin and collagen supplements help with hair loss? Evidence for either in patients without documented deficiency is weak. Biotin supplementation also interferes with thyroid function and troponin lab assays, which is an underappreciated risk.
Is hair loss covered by insurance? Pattern hair loss treatment is generally classified as cosmetic. Some HSA/FSA accounts cover prescribed medications and physician visits, but surgical procedures are typically excluded.
How accurate is self-staging with the Norwood scale? Reasonably accurate for clear-cut cases (Norwood 1 vs. Norwood 5), but borderline stages, especially 2 vs. 3, are where most people get tripped up. Lighting, hair wetness, and camera angle all affect how the hairline looks in photos.
References
- Hamilton JB. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci. 1951;53(3):708-728.
- Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359-1365.
- Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men: short version. J Eur Acad Dermatol Venereol. 2018;32(1):11-22.
- American Academy of Dermatology Association. Hair loss: diagnosis and treatment. AAD clinical guidance.
- Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss. J Am Acad Dermatol. 2006;55(6):1014-1023.
- Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104-109.
- Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651.
- Gentile P, Garcovich S. Systematic review of platelet-rich plasma use in androgenetic alopecia compared with minoxidil, finasteride, and adult stem cell-based therapy. Int J Mol Sci. 2020;21(8):2702.
- Kassira S, Korta DZ, Chapman LW, Dann F. Frontal fibrosing alopecia: a review. J Am Acad Dermatol. 2017;77(2):209-212.
- Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777-2786.
Educational content, not medical advice. This article summarizes peer-reviewed sources and clinical guidelines for general informational purposes and does not constitute medical advice, diagnosis, or treatment. Hair loss has multiple possible causes, and an in-person dermatology evaluation is the appropriate starting point for any individual case. Do not start, stop, or change medications based on this article.
Privacy framing for AI-based assessment tools: AI hair-loss screening tools such as Myhairline.ai analyze user-submitted photos using MediaPipe Face Mesh 468-landmark detection. Photos are not stored, and no account is required. The AI output is educational, not diagnostic.
